Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives Buy Rating from Chardan Capital

Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “buy” rating reissued by stock analysts at Chardan Capital in a research report issued on Wednesday,Benzinga reports. They currently have a $300.00 price objective on the biopharmaceutical company’s stock. Chardan Capital’s target price indicates a potential upside of 22.35% from the company’s current price.

Other equities analysts also recently issued research reports about the company. HC Wainwright lifted their price objective on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a “buy” rating in a research report on Monday. Raymond James lifted their price target on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. Sanford C. Bernstein lowered their price objective on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. Needham & Company LLC reissued a “buy” rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday. Finally, Wolfe Research lowered Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $303.83.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $245.20 on Wednesday. The firm has a 50-day simple moving average of $254.21 and a 200-day simple moving average of $262.72. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The stock has a market capitalization of $31.74 billion, a price-to-earnings ratio of -112.99 and a beta of 0.35. Alnylam Pharmaceuticals has a 52 week low of $141.98 and a 52 week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). On average, equities analysts predict that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 52,592 shares of the business’s stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now owns 11,989 shares in the company, valued at $3,416,865. The trade was a 81.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40. Following the completion of the sale, the executive vice president now directly owns 12,881 shares in the company, valued at approximately $3,240,344.36. This represents a 10.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 72,986 shares of company stock worth $20,397,849. Company insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Huntington National Bank raised its position in shares of Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 45 shares in the last quarter. Larson Financial Group LLC raised its holdings in Alnylam Pharmaceuticals by 187.2% during the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 73 shares in the last quarter. Hollencrest Capital Management purchased a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $29,000. R Squared Ltd acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $33,000. Finally, OFI Invest Asset Management purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $35,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.